|
|
Volumn 98, Issue 8, 2006, Pages 510-512
|
|
Intraperitoneal therapy for advanced ovarian cancer: will it become standard care?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CISPLATIN;
CYCLOPHOSPHAMIDE;
PACLITAXEL;
ADJUVANT CHEMOTHERAPY;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
FEMALE;
HEALTH CARE ORGANIZATION;
HUMAN;
INTRAPERITONEAL DRUG ADMINISTRATION;
OVARY TUMOR;
PATHOLOGY;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL;
TREATMENT OUTCOME;
UNITED STATES;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CHEMOTHERAPY, ADJUVANT;
CISPLATIN;
CLINICAL TRIALS;
CYCLOPHOSPHAMIDE;
FEMALE;
HUMANS;
INJECTIONS, INTRAPERITONEAL;
NATIONAL INSTITUTES OF HEALTH (U.S.);
OVARIAN NEOPLASMS;
PACLITAXEL;
RANDOMIZED CONTROLLED TRIALS;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
UNITED STATES;
|
|
EID: 33646445770
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djj173 Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
